V Autologous Bone Marrow Transplantation_2.pdf - Blog Science ...

More documents

Recommendations

Info

B Bostrom Can Maximal Dose Chemotherapy with Marrow Growth Factors Replace Autologous Bone Marrow Transplantation? 861 G Kusminsky, A Lemus, M Dictar, AM Chirife, R Bayo, D Ceraso and B Konne Subcutaneous Administration of Recombinant Human Granulocyte- Macrophage Colony Stimulating Factor (rhGM-CSF) in Autologous Bone Marrow Transplantation 869 A Elias, R Mazanet, C Wheeler, K Anderson, L Ayash, G Schwartz, I Tepler, S Pap, R Gonin, J Critchlow, L Schnipper, J Griffin, E Frei andKAntman Peripheral Blood Progenitor Cells (PBPC): Two Protocols Using GM-CSF Potentiated Progenitor Cell Collection 875 B. Pre-Clinical E Wunder, H Sowala, H Liang, Ph Henon The Role of Monocytes in the Stimulation of Progenitor Cells 881 C. Modifiers MK Brenner, HE Heslop, D Gottlieb, P Oblakowskt, C Betto-Fernandez, HG Prentice and JE Reittie Use of Interleukin-2 After Autologous Bone Marrow Transplantation 893 SESSION 11: CONCLUDING REMARKS RPGale Meeting Report: Autotransplants: Now and in the Future 905 JM Vose and JO Armitage Summary: Transplantation for Lymphomas 911 xvi
PREFACE The Fifth International Symposium on Autologous Bone Marrow Transplantation was a real success! The title of the Proceedings, "Autologous Bone Marrow Transplantation", does not reflect the significance of peripheral blood as an alternate source of stem cells. Peripheral stem cell transplantation was one of the highlights of this symposium. Another highlight was the session on breast cancer. The rapid improvement of results of high dose chemotherapy with stem cell support in this disease may have caused a headache for the insurance carriers but not for the clinical investigators and certainly not for our patients! In the laboratory new strategies are under development which may have reached the clinic by the time of die next symposium. Last but not least, explosive progress with hematopoietic growth factors introduces a new era in the field of high dose therapy and stem cell transplantation. Over 4000 autotransplants were performed in 1989 and in 1990, a marked difference compared with 10 transplants in 1976! This expanding field needs cohesiveness of investigators to enhance effective progress. This symposium has been, is and will be, one of the main instruments to achieve this. Therefore, plans are underway for the next symposium to be held here in July 1992. Again, welcome to Omaha! xvii
Page 3: UBiv»rstt5ts-Krauk8Biiaas Eppendor
Page 6 and 7: Publication of these proceedings is
Page 8 and 9: B. Relapse JE Sanders, RHill, F App
Page 10 and 11: SESSION 3: CHRONIC MYELOGENOUS LEUK
Page 12 and 13: JP Eder and BA Teicher New Agents i
Page 14 and 15: AMCarella, P Codier, A Congiu, E Ga
Page 16 and 17: G Rosti, M Leoni, L Atbertazd, R Sa
Page 21: ACKNOWLEDGEMENTS The organizers tha
Page 24 and 25: 4 Session 1: Acute Myelogenous Leuk
Page 26 and 27: 6 Session 1: Acute Myelogenous Leuk
Page 29 and 30: 9 ABMT vs. Chemotherapy in Adults:
Page 31: 11 ABMT vs. Chemotherapy in Adults:
Page 34 and 35: 14 Session 1: Acute Myelogenous Leu
Page 43 and 44: 23 Role of Marrow Purging AUTOLOGOU
Page 45 and 46: Role of Marrow Purging 25 the leuke
Page 47 and 48: 27 Role of Marrow Purging The distr
Page 49 and 50: Role of Marrow Purging 29 REFERENCE
Page 51 and 52: 31 Role of Marrow Purging TABLE 2 A
Page 53 and 54: 33 Role of Marrow Purging FIGURE 3
Page 55 and 56: 35 Role of Marrow Purging FIGURE 7
Page 57 and 58: 37 ABMT: An Eastern Cooperative Onc
Page 59 and 60: 39 ABMT: An Eastern Cooperative Onc
Page 61: 41 ABMT: An Eastern Cooperative Onc
Page 68 and 69:
48 Session 1: Acute Myelogenous Leu
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 97 and 98:
77 BAVC Followed by Unpurged Marrow
Page 99 and 100:
79 BAVCFollowedby Unpurged Marrow I
Page 101 and 102:
81 ABMT with Unpurged Marrow AUTOLO
Page 103 and 104:
ABMT with Unpurged Marrow 83 Kaplan
Page 105 and 106:
85 ABMT with Unpurged Marrow 4. Gol
Page 107 and 108:
87 ABMT with Unpurged Marrow TABLE
Page 109:
89 ABMT with Unpurged Marrow FIGURE
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
100 Session 1: Acute Myelogenous Le
Page 122 and 123:
102 Session 1: Acute Myelogenous Le
Page 125 and 126:
105 ABMT with 4-HC Purged Marrow AU
Page 127 and 128:
107 ABMT with 4-HC Purged Marrow RE
Page 129 and 130:
109 ABMT with 4-HC Purged Marrow de
Page 131 and 132:
ABMT wüh 4-HC Purged Marrow TABLE
Page 133 and 134:
113 MonoclonalAntibody-PurgedABMT N
Page 135 and 136:
115 Monoclonal Antibody-PurgedABMT
Page 137 and 138:
117 MonoclonalAntibody-PurgedABMT (
Page 139 and 140:
119 MonoclonalAntibody-PurgedABMT R
Page 141 and 142:
121 MonoclonalAntïbody-PurgedABMT
Page 143 and 144:
123 Prognostic Factors for Hematolo
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
135 Cell Proliferation Studies with
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Cell Proliferation Studies with AST
Page 163 and 164:
Page 165 and 166:
145 Detection of Minimal Residual D
Page 167 and 168:
Page 169:
Page 172 and 173:
152 Session 2: Acute Lymphocytic Le
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 187 and 188:
167 ABMT: Report from Dana Farber C
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
177 Bone Marrow Purging BONE MARROW
Page 199 and 200:
179 Bone Marrow Purging intermediat
Page 201 and 202:
181 Bone Marrow Purging Clinical Ou
Page 203 and 204:
183 Bone Marrow Purging 12. Ramsay
Page 205 and 206:
185 Bone Marrow Purging TABLE 4 Sum
Page 207:
187 Bone Marrow Purging FIGURE 3 Di
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
202 Session 2: Acute Lymphocytic le
Page 225 and 226:
205 Chemotherapy Regimens and BMT I
Page 227 and 228:
207 Chemotherapy Regimens and BMT F
Page 229 and 230:
209 Chemotherapy Regimens and BMT F
Page 231 and 232:
211 Detection of Minimal Residual L
Page 233 and 234:
Page 235 and 236:
Page 237:
Page 240 and 241:
220 Session 3: Chronic Myelogenous
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 275 and 276:
255 Approaches to Prevent Relapse A
Page 277:
257 Approaches to Prevent Relapse F
Page 280 and 281:
260 Session 4: Supportive Care in g
Page 282 and 283:
262 Session 4: Supportive Care REFE
Page 284 and 285:
264 Session 4: Supportive Care TABL
Page 287 and 288:
267 Gram-Positive Septicemia CHARAC
Page 289 and 290:
269 Cram-Positive Septicemia treatm
Page 291 and 292:
271 Gram-Positive Septicemia Guiot
Page 293 and 294:
273 Ann' Fungal Therapy FLUCONAZOLE
Page 295 and 296:
275 Anti Fungal Therapy > different
Page 297 and 298:
277 Ana Fungal Therapy 19. Kroger H
Page 299:
279 Ana Fungal Therapy TABLE 2 INTE
Page 302 and 303:
282 Session 4: Supportive Care port
Page 304 and 305:
284 Session 4: Supportive Care infe
Page 306 and 307:
286 Session 4: Supportive Care REFE
Page 309 and 310:
289 COBE Spectra BONE MARROW CONCEN
Page 311 and 312:
291 COBE Spectra precursor assay (C
Page 313 and 314:
293 COBE Spectra TABLE 2 DEPLETION
Page 315:
295 COBE Spectra FIGURE 2 PROCEDURE
Page 318 and 319:
298 Session 4: Supportive Care The
Page 320 and 321:
300 Session 4: Supportive Care DISC
Page 322 and 323:
302 Session 4: Supportive Care 14.
Page 324 and 325:
304 Session 4: Supportive Care FIGU
Page 326 and 327:
306 Session 5: Breast Cancer - Meta
Page 328 and 329:
308 Session S: Breast Cancer - Meta
Page 330 and 331:
Page 333 and 334:
313 High Dose Therapy wäh ABMT HIG
Page 335 and 336:
315 High Dose Therapy with ABMT Thi
Page 337 and 338:
317 High Dose Therapy with ABMT for
Page 339 and 340:
319 High Dose Therapy with ABMT aut
Page 341:
321 High Dose Therapy with ABMT TAB
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
338 Session S: Breast Cancer - Meta
Page 360 and 361:
Page 363 and 364:
343 High Dose Therapy and ASC Rescu
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
353 High Dose Chemotherapy andBM HI
Page 375 and 376:
355 High Dose Chemotherapy and BMT
Page 377 and 378:
357 High Dose Chemotherapy and BMT
Page 379 and 380:
359 High Dose Cliemotherapy and BMT
Page 381:
361 High Dose Qiemotherapy and BM T
Page 384 and 385:
364 Session 5: Breast Cancer - Pre-
Page 386 and 387:
Page 388 and 389:
368 Session S: Breast Cancer - Pre-
Page 390 and 391:
Page 393 and 394:
373 New Agents in Chemotherap NEW A
Page 395 and 396:
375 New Agents in Chemotherapy of a
Page 397:
377 New Agents in Chemotherap 17. M
Page 400 and 401:
380 Session 6: Breast Cancer- Pre-M
Page 402 and 403:
Page 404 and 405:
Page 406 and 407:
Page 408 and 409:
Page 410 and 411:
Page 413 and 414:
393 ABMT: Cooperative Pilot Study R
Page 415 and 416:
Page 417 and 418:
397 ABMT: Cooperative PUot Study Re
Page 419 and 420:
Page 421 and 422:
401 ÄBMT' Cooperative Pilot Study
Page 423 and 424:
Page 425 and 426:
405 Factors Affecting ABMT Results
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
411 Parma Pilot Study RELAPSE OF MA
Page 433 and 434:
413 Parma Pilot Study ABMT in the p
Page 435 and 436:
415 Parma Pilot Study Netherlands;
Page 437:
417 Parma Pilot Study FIGURE 1 PARM
Page 440 and 441:
420 Session 6: Lymphoma - Non-Hodgk
Page 442 and 443:
Page 444 and 445:
Page 447 and 448:
427 High Dose Etoposide and Melphal
Page 449 and 450:
Page 451:
Page 454 and 455:
Page 456 and 457:
436 Session 6: Lymphoma • Non-Hod
Page 458 and 459:
Page 460 and 461:
Page 462 and 463:
Page 464 and 465:
444 Session 6: Lymphoma • Non-Hod
Page 466 and 467:
Page 468 and 469:
Page 470 and 471:
Page 472 and 473:
Page 474 and 475:
454 Session 6: Lymphoma - Low Grade
Page 476 and 477:
Page 478 and 479:
Page 480 and 481:
Page 482 and 483:
Page 485 and 486:
465 Ablative Therapy with ABMT ABLA
Page 487 and 488:
467 Ablative Therapy with ABMT RESU
Page 489 and 490:
469 Ablative Therapy with ABMT REFE
Page 491:
471 Ablative Therapy with ABMT TABL
Page 494 and 495:
474 Session 6: Non-Hodgkin's Lympho
Page 496 and 497:
Page 498 and 499:
Page 500 and 501:
Page 502 and 503:
Page 504 and 505:
Page 507 and 508:
487 Studies with Sequential Transpl
Page 509 and 510:
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
Page 517 and 518:
Page 519:
Page 522 and 523:
502 Session 6: Lymphoma - Hodgkin's
Page 524 and 525:
Page 526 and 527:
Page 528 and 529:
Page 530 and 531:
Page 532 and 533:
Page 534 and 535:
Page 536 and 537:
Page 538 and 539:
518 Session 6: Lymphoma - Hodgkin*s
Page 540 and 541:
520 Session 6: Lymphoma - Hodgldn's
Page 542 and 543:
Page 544 and 545:
Page 546 and 547:
Page 549 and 550:
529 ABMT and Cooperative Group Tria
Page 551 and 552:
531 ABMT and Cooperative Group Tria
Page 553 and 554:
533 ABUT and Cooperative Group Tria
Page 555 and 556:
535 ABMTand Cooperative Group Trial
Page 557:
537 ABMTandCooperative Group Trials
Page 560 and 561:
540 Session 6: Lymphoma PATIENTS AN
Page 562 and 563:
542 Session 6: Lymphoma RESULTS Lym
Page 564 and 565:
544 Session 6: Lymphoma with TBI; t
Page 566 and 567:
546 Session 6: Lymphoma TABLE 1 CON
Page 568 and 569:
548 Session 6: Lymphoma TABLE 5 PAT
Page 571 and 572:
551 Prospects for the Future AUTOGR
Page 573 and 574:
553 Prospects for the Future relaps
Page 575 and 576:
555 Prospects for the Future amelio
Page 577 and 578:
557 Prospects for the Future which
Page 579 and 580:
559 Prospects for the Future OVERVI
Page 581:
561 Prospects for the Future FIGURE
Page 584 and 585:
564 Session 6: Lymphoma - Myeloma M
Page 586 and 587:
566 Session 6: Lymphoma - Myeloma R
Page 588 and 589:
568 Session 6: Lymphoma - Myeloma 9
Page 590 and 591:
570 Session 6: Lymphoma - Myeloma F
Page 592 and 593:
572 Session 6: Lymphoma - Myeloma I
Page 594 and 595:
574 Session 6: Lymphoma - Myeloma w
Page 596 and 597:
576 Session 6: Lymphoma - Myeloma T
Page 598 and 599:
578 Session 6: Lymphoma - Myeloma T
Page 600 and 601:
580 Session 6: Lymphoma - Myeloma F
Page 602 and 603:
582 Session 6: Lymphoma - Myeloma A
Page 604 and 605:
584 Session 6: Lymphoma - Myeloma R
Page 607 and 608:
587 Neuroblastoma in Children OUTCO
Page 609 and 610:
589 Neuroblastoma in Children the 3
Page 611 and 612:
591 Neuroblastoma in Children Remis
Page 613 and 614:
593 Neuroblastoma in Children TABLE
Page 615 and 616:
595 Neuroblastoma in Children FIGUR
Page 617:
597 Neuroblastoma in Children FIGUR
Page 620 and 621:
600 Session 7: Solid Tumors and Eto
Page 622 and 623:
602 Session 7: Solid Tumors patient
Page 624 and 625:
604 Session 7: Solid Tumors state a
Page 626 and 627:
606 Session 7: Solid Tumors TABLE l
Page 628 and 629:
608 Session 7: Solid Tumors TABLE 2
Page 630 and 631:
Page 632 and 633:
612 Session 7: Solid Tumors was ass
Page 634 and 635:
614 Session 7: Solid Tumors microme
Page 636 and 637:
616 Session 7: Solid Tumors 13. Dim
Page 638 and 639:
Page 640 and 641:
620 Session 7: Solid Tumors Protoco
Page 642 and 643:
622 Session 7: Solid Tumors at diag
Page 644 and 645:
624 Session 7: Solid Tumors immunol
Page 646 and 647:
626 Session 7: Solid Tumors 3. Favr
Page 648 and 649:
628 Session 7: Solid Tumors TABLE I
Page 650 and 651:
630 Session 7: Solid Tumors TABLE m
Page 652 and 653:
632 Session 7: Solid Tumors childre
Page 654 and 655:
634 Session 7: Solid Tumors 6. Doug
Page 656 and 657:
636 Session 7: Solid Tumors FIGURE
Page 658 and 659:
638 Session 7: Solid Tumors BCNU wa
Page 660 and 661:
640 Session 7: Solid Tumors enhance
Page 662 and 663:
642 Session 7: Solid Tumors constan
Page 664 and 665:
Page 667 and 668:
647 Germ Cell Neoplasms DOSE INTENS
Page 669 and 670:
649 Germ &tt Neoplasms Indiana Univ
Page 671 and 672:
651 Germ CeUNeophsms Non-hematologi
Page 673:
653 Germ Cell Neoplasms Cancer. A S
Page 676 and 677:
656 Session 7: Solid Tumors Twelve
Page 678 and 679:
658 Session 7: Solid Tumors 5. Rich
Page 681 and 682:
661 Dose Intensive Therapy DOSE INT
Page 683 and 684:
663 Dose Intensive Therapy compared
Page 685 and 686:
665 Dose Intensive Therapy of thera
Page 687:
6 6 7 Dose Intensive Therapy TABLE
Page 690 and 691:
670 Session 7: Solid Tumors drugs c
Page 692 and 693:
672 Session 7: Solid Tumors cisplat
Page 694 and 695:
Page 697 and 698:
677 Conditioning Regimen for BMT BU
Page 699 and 700:
679 Conditioning Regimen for BMT To
Page 701 and 702:
681 Conditioning Regimen for BMT TA
Page 703 and 704:
683 Conditioning Regimen for BMT TA
Page 705:
685 Conditioning Regimen for BMT FI
Page 708 and 709:
688 Session 7: Solid Tumors consist
Page 710 and 711:
Page 713 and 714:
693 ABMT for Arthritis in Rats REMI
Page 715 and 716:
695 ABMT for Arthritis in Rats It i
Page 717:
697 ABMT for Arthritis in Rats FIGU
Page 720 and 721:
700 Session 8: New Avenues MATERIAL
Page 722 and 723:
702 Session 8: New Avenues positive
Page 724 and 725:
704 Session 8: New Avenues Previous
Page 726 and 727:
706 Session 8: New Avenues FIGURE 1
Page 728 and 729:
Page 730 and 731:
Page 732 and 733:
712 Session 8: New Avenues to thiou
Page 734 and 735:
714 Session 8: New Avenues analysis
Page 736 and 737:
716 Session 8: New Avenues Liver vo
Page 738 and 739:
718 Session 8: New Avenues TABLE 1
Page 740 and 741:
Page 742 and 743:
Page 744 and 745:
724 Session 8: New Avenues 1, dose-
Page 746 and 747:
726 Session 8: New Avenues Bone mar
Page 748 and 749:
728 Session 8: New Avenues ACKNOWLE
Page 750 and 751:
730 Session 8: New Avenues TABLE 1
Page 752 and 753:
Page 754 and 755:
734 Session 8: New Avenues transfer
Page 756 and 757:
736 Session 8: New Avenues a concen
Page 758 and 759:
738 Session 8: New Avenues Beta 5'U
Page 760 and 761:
740 Session 8: New Avenues 5. Stoec
Page 762 and 763:
Page 764 and 765:
Page 766 and 767:
Page 768 and 769:
Page 771 and 772:
751 Immunocytochemical Detection of
Page 773 and 774:
Page 775 and 776:
Page 777 and 778:
Page 779 and 780:
Page 781 and 782:
Page 783 and 784:
763 Immunotherapy: Post-ABMT Implic
Page 785 and 786:
Page 787 and 788:
Page 789 and 790:
Page 791 and 792:
771 Immunostimulation Post-ABMT IMM
Page 793 and 794:
773 Immunostimulation Post-ABMT are
Page 795 and 796:
775 Immunostimulation Post-ABMT cul
Page 797 and 798:
Ill Immunostimulation Post-ABMT 4.
Page 799 and 800:
779 Immunostimulation Post-ABMT FIG
Page 801 and 802:
781 ImmuMstimuIation Post-ABMT FIGU
Page 803 and 804:
783 Myelosuppressive Chemotherapy P
Page 805 and 806:
785 Myelosuppressive Chemotherapy P
Page 807 and 808:
787 Myelosuppressive Chemotherapy m
Page 809 and 810:
789 Myelosuppressive Chemotherapy T
Page 811 and 812:
791 Mobilization Techniques THE ROL
Page 813 and 814:
793 Mobilization Techniques Cell an
Page 815 and 816:
795 Mobilization Techniques 8. Bran
Page 817 and 818:
797 Mobilization Techniques FIGURE
Page 819:
799 Mobilization Techniques FIGURE
Page 822 and 823:
802 Session 9: Peripheral Stem Ceil
Page 824 and 825:
804 Session 9: Peripheral Stem Cell
Page 826 and 827:
806 Session 9: Peripheral Stern Cel
Page 828 and 829:
Page 830 and 831:
Page 832 and 833:
Page 834 and 835:
Page 836 and 837:
Page 838 and 839:
Page 840 and 841:
Page 843 and 844:
823 Acute Myeloid Leukemia PERIPHER
Page 845 and 846:
825 Acute Myeloid Leukemia leukemic
Page 847:
827 Acute Myeloid Leukemia after hi
Page 850 and 851:
Page 852 and 853:
Page 854 and 855:
Page 857 and 858:
837 Relapsed Lymphomas and Marrow M
Page 859 and 860:
839 Relapsed Lymphomas and Marrow M
Page 861 and 862:
841 High Risk Myeloma AUTOLOGOUS BL
Page 863 and 864:
843 High Risk Myeloma analysis for
Page 865 and 866:
845 High Risk Myeloma encountered,
Page 867 and 868:
847 High Risk Myeloma 10. Debecker
Page 869:
849 High Risk Myeloma TABLE 2 ABSCT
Page 872 and 873:
852 Session 10: Hematopoietic Growt
Page 874 and 875:
Page 876 and 877:
Page 878 and 879:
Page 880 and 881:
Page 882 and 883:
Page 884 and 885:
Page 886 and 887:
Page 888 and 889:
Page 890 and 891:
Page 892 and 893:
Page 894 and 895:
Page 896 and 897:
Page 898 and 899:
Page 901 and 902:
881 Role of Monocytes THE ROLE OF M
Page 903 and 904:
883 Role of Monocytes cells, always
Page 905 and 906:
885 Role of Monocytes CONCLUSION Th
Page 907 and 908:
887 Role of Monocytes TABLE 2 Proge
Page 909 and 910:
889 Role of Monocytes FIGURE 1 cont
Page 911 and 912:
891 Role of Monocytes FIGURE 3 Kine
Page 913 and 914:
893 InterleuIdn-2 Post-ABMT USE OF
Page 915 and 916:
895 Iníerkukin-2 Posí-ABMT Specif
Page 917 and 918:
897 Interleukin-2 Post-ABMT years;
Page 919 and 920:
899 Interieukin-2 Post-ABMT 19. Lau
Page 921 and 922:
901 Interleukin-2 Post-ABMT TABLE 2
Page 923 and 924:
903 Interleuldn-2 Post-ABMT FIGURE
Page 925 and 926:
905 Autotransplants: Present and Fu
Page 927 and 928:
Page 929:
Page 932 and 933:
912 Session 11: Concluding Remarks
Page 935 and 936:
CONTRIBUTORS Tauseef Ahmed, M.D., N
Page 937 and 938:
Anthony Elias, M.D., Dana Färber C
Page 939 and 940:
Per Ljungman, M.D., Ph.D., Departme
Page 941:
Yoichi Takaue, M.D., Department of
show all

V Autologous Bone Marrow Transplantation_2.pdf - Blog Science ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?